The use of new aceclofenac dosage forms in patients with osteoarthrosis in real-life clinical practice

A new convenient dosage form of aceclofenac (sashet bags) has recently been launched on the Russian market. The powder in a single sashet bag weighs 3 g, which corresponds to 100 mg of the active ingredient per tablet. A prospective study (including evaluation of the effectiveness and safety of the sashet form of aceclofenac in real-life clinical practice) was carried out in 40 outpatients with osteoarthrosis (OA) of the knee and hip joints during 2 weeks. A clear pain relief by 25% vs the beginning of therapy was observed; joint stiffness decreased by 34%; joint function improved by 17%; and the total WOMAC score decreased by 18% by the end of the therapy (262.7±127.7 vs 198.5±111.6; 88.5±42.21
vs 57.7±32.6; 789.9±307.2 vs 650.6±242.6 and 1087.7±369.3 vs 886.4±326.0, p<0.05, respectively, in all cases). The results of our surveillance study in real-life clinical practice have shown that sashet aceclofenac rapidly relieves pain and reduces joint stiffness, thus improving the functional condition of joints. Adverse effects related to the gastrointestinal tract were observed in only one (2.5%) patient when using sashet aceclofenac. The drug in this dosage form can be recommended as an effective and safe agent, especially for patients who typically receive non-steroidal anti-inflammatory drugs in liquid forms.

1. <div><p>Галушко ЕА. Медико-социальная зна-</p><p>чимость ревматических заболеваний. Ав-</p><p>тореферат диссертации на соискание уче-</p><p>ной степени доктора медицинских наук.</p><p>Москва; 2011. [Galushko EA. Mediko-sot-</p><p>sial'naya znachimost' revmaticheskikh zabole-</p><p>vanii. Avtoreferat dissertatsii na soiskanie</p><p>uchenoi stepeni doktora meditsinskikh nauk.</p><p>Moscow; 2011.]</p><p>Алексеев ВВ. Современные представле-</p><p>ния и основные принципы терапии боли.</p><p>Спецвыпуск Болевой синдром. Русский</p><p>медицинский журнал. 2011;19:6–11.</p><p>[Alekseev VV. Sovremennye predstavleniya</p><p>i osnovnye printsipy terapii boli. Spetsvypusk</p><p>Bolevoi sindrom. Russkii meditsinskii zhur-</p><p>nal. 2011;19:6–11.]</p><p>Голубев ВЛ, Данилов А.Б. Психологи-</p><p>ческие установки пациента и пережива-</p><p>ние боли. Спецвыпуск Болевой синдром.</p><p>Русский медицинский журнал.</p><p>;18:2–5. [Golubev VL, Danilov A.B.</p><p>Psikhologicheskie ustanovki patsienta i</p><p>perezhivanie boli. Spetsvypusk Bolevoi sin-</p><p>drom. Russkii meditsinskii zhurnal.</p><p>;18:2–5.]</p><p>Sowers JR, White WB, Pitt B, et al. The</p><p>effects of cyclooxygenase-2 inhibitors and</p><p>nonsteroidal anty-inflammatory therapy on</p><p>-hour blood pressure in patients with</p><p>hypertension, osteoarthritis and type 2 dia-</p><p>betes mellitus. Arch Intern Med.</p><p>;165(2):161–8. DOI:</p><p>http://dx.doi.org/10.1001/archinte.165.2.161.</p><p>Ray WA, Varas-Lorenzo C, Chung CP,</p><p>et al. Circ Cardiovasc Qual Outcomes.</p><p>May;2(3):155–63. DOI: 10.1161/CIR-</p><p>COUTCOMES.108.805689.</p><p>Epub 2009 May 5.</p><p>Рекомендации OARSI по лечению ос-</p><p>теоартроза коленных и тазобедренных су-</p><p>ставов. Часть III; 2010 г. [Rekomendatsii</p><p>OARSI po lecheniyu osteoartroza kolennykh i</p><p>tazobedrennykh sustavov.</p><p>Сhast' III; 2010 g.]</p><p>Ding С. Do NSDIDs affect the progres-</p><p>sion of osteoarthritis? Inflammation.</p><p>;26(3):139–42.</p><p>Dingle JT. The effect of nonsteroidal anti-</p><p>inflammatory drugs on human articular carti-</p><p>lage glycosaminoglycan synthesis.</p><p>Osteoarthritis Cartilage. 1999;7(3):313–4.</p><p>DOI:</p><p>http://dx.doi.org/10.1053/joca.1998.0176.</p><p>Mastbergen SC, Jansen NWD,</p><p>Bijlsma JWJ, et al. Differential direct effects</p><p>of cyclo-oxygenase-1/2 inhibition on proteo-</p><p>glycan turnover of human osteoarthritis сarti-</p><p>lage: an in vitro study. Arthritis Res Ther.</p><p>;8(1):R2. DOI: 1186/ar1846.</p><p>Akimoto H, Yamazaki R, et al. A major</p><p>metabolite og aceclofenac 4-hydroxyace-</p><p>clofenac suppresses the interleukin-1 induced</p><p>production of promatrix metalloprpteinases</p><p>and relese of sulfated- glycosaminoglycans</p><p>from rabbit articular chondrocytes. Eur J</p><p>Pharmacol. 2000;401(3):429–36. DOI:</p><p>http://dx.doi.org/10.1016/S0014-</p><p>(00)00472-6.</p><p>Blot L, Marselis A, Devogelaer J-P, et al.</p><p>Effects of diclofenac, aceclofenac and</p><p>meloxicam on the metabolism of proteogly-</p><p>cans and hyaluronan in osteoarthritic human</p><p>cartilage. Br J Pharmacol.</p><p>;131(7):1413–21. DOI:</p><p>http://dx.doi.org/10.1038/sj.bjp.0703710.</p><p>Batlle-Gualda E, Roman Ivorra J,</p><p>Martin-Mola E, et al. Aceclofenac vs parac-</p><p>etamol in the management of systematic</p><p>osteoarthritis of the knee: a double blind 6</p><p>week randomized controlled trial.</p><p>Osteoarthritis Cartilage. 2007;15(8):900–8.</p><p>Epub 2007 Mar 26. DOI:</p><p>http://dx.doi.org/10.1016/j.joca.2007.02.008.</p><p>Korsanoff D, Frericck H, Bowdler J,</p><p>et al. Aceclofenac is well-tolerated alternarive</p><p>to naproxen in the treatment osteoarthritis.</p><p>Clin Rheumatol. 1997;16(1):32–8. DOI:</p><p>http://dx.doi.org/10.1007/BF02238760.</p><p>Peris F, Bird H, Semi U, et al. Treatment</p><p>compliance and safety of aceclofenac versus</p><p>standard NSAIDs in patients with common</p><p>arthritic disorders: a meta-analysis. Eur J</p><p>Rheumatol Inflamm. 1996;(16):37–45.</p><p>Huskisson E, Irani M, Murray F. A large</p><p>prospective open-label, multicentre SAMM</p><p>study, comparing the safety of aceclofenac</p><p>with diclofenac in patients withrheumatic dis-</p><p>ease. Eur J Rheumatol Inflamm.</p><p>;7(1):1–7.</p><p>Zabala Gamarra M. Efficacy and tolera-</p><p>bility of aceclofenac in a 3-month open trial</p><p>in the treatment of gonarthrosis. Dolor</p><p>Inflamation 1993;(1):3–7.</p><p>Diaz C, Rodriguez A, Geli C, et al.</p><p>Efficacy and tolerability of aceclofenac versus</p><p>diclofenac in the treatment of knee</p><p>osteoarthritis. A multicenter study. Eur J</p><p>Rheumatol Inflamm. 1996;(16):17–22.</p><p>Calin A, Murrey FE. Aceclofenac: side</p><p>effects and safety. Eur J Rheumatol Inflamm.</p><p>;(16):13–6.</p><p>Korsanoff D, Frerick H, Bowdler J,</p><p>Montull E. Aceclofenac is well-tolerated</p><p>alternative to naproxen in the treatment</p><p>osteoarthritis. Clin Rheumatol.</p><p>;16(1):32–8. DOI:</p><p>http://dx.doi.org/10.1007/BF02238760.</p><p>Pereя Busquer M, Calero E, Rodriguez M,</p><p>et al. Comparison of aceclofenac with piroxi-</p><p>cam in the treatment of osteoarthritis.</p><p>Clin Rheumatol. 1997;16(2):154–9. DOI:</p><p>http://dx.doi.org/10.1007/BF02247844.</p><p>Шарапова ЕП, Алексеева ЛИ,</p><p>Таскина ЕА и др. Ацеклофенак в терапии</p><p>остеоартроза. Лечащий врач. 2012;8:90–5.</p><p>[Sharapova EP, Alekseeva LI, Taskina EA,</p><p>et al. Atseklofenak v terapii osteoartroza.</p><p>Lechashchii vrach. 2012;8:90–5.]</p></div><br />